New injection shows promise for controlling severe eczema flares

NCT ID NCT06723405

Completed Disease control Sponsor: Evommune, Inc. Source: ClinicalTrials.gov ↗

Summary

This study tested whether an intravenous medication called EVO301 could help control moderate to severe eczema in adults. 71 participants with significant eczema covering at least 10% of their body received either the drug or a placebo. Researchers measured changes in skin severity, itch intensity, and overall appearance to see if the treatment was effective and safe.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Clinical Trials New Zealand Ltd

Hamilton, 3204, New Zealand
Cornerstone Dermatology

Coorparoo, QLD 4151, Australia
Momentum Clinical Research Darlinghurst

Darlinghurst, NSW 2010, Australia
Momentum Clinical Research Dunedin

Dunedin, 9016, New Zealand
Momentum Clinical Research Kapiti

Paraparaumu, 5032, New Zealand
Momentum Clinical Research Lower Hutt

Hutt Central, 5010, New Zealand
Momentum Clinical Research Pukekohe

Pukekohe, 2120, New Zealand
Optimal Clinical Trials

Auckland, 1010, New Zealand
Optimal Clinical Trials North

Auckland, 0632, New Zealand
Pacific Clinical Research Network (PCRN) Auckland

Auckland, 0622, New Zealand
Pacific Clinical Research Network (PCRN) Christchurch

Christchurch, 8013, New Zealand
Pacific Clinical Research Network (PCRN) Tasman

Nelson, 7011, New Zealand

Conditions

Explore the condition pages connected to this study.

ATOPIC DERMATITIS (AD) ECZEMA ECZEMA ATOPIC DERMATITIS